Marksans Pharma arm gets marketing authorization for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution in UK
Mumbai: Marksans Pharma Limited, an Indian pharmaceutical company, has announced that its wholly owned subsidiary in the UK, Relonchem
Limited, has received marketing authorization for the product Oxybutynin hydrochloride
2.5mg/5ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.
This marks the latest in a series of approvals for the company.
At the end of May, Relonchem also secured UK MHRA approval for Metformin Hydrochloride 500mg/5ml Oral Solution, a widely prescribed first-line treatment for type 2 diabetes.
Earlier in May, the company received marketing authorization in UK for Sennosides 7.5 mg Tablets and Gabapentin 50 mg/ml oral solution.
Read also: Marksans Pharma arm Relonchem gets marketing authorization for Sennosides Tablets in UK
In March, the UK MHRA granted approval for Baclofen 10 mg Tablets, a medication used to relax specific muscles in the body, relieving spasms, cramps, and tightness associated with multiple sclerosis or spinal injuries.
Read also: Marksans Pharma arm gets marketing authorization for muscle relaxant tablets in UK
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.
In February, Relonchem received authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell’s Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).
Marksans Pharma Limited, headquartered at Mumbai, India, is
engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in
the global markets. The company’s manufacturing facilities located in India, USA and UK are
approved by several leading regulatory agencies including USFDA, UKMHRA and
Australian TGA. The company’s product portfolio spreads over major therapeutic
segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.
